System Accuracy Assessment of a Blood Glucose Meter With Wireless Internet Access Associated With Unusual Hypoglycemia Patterns in Clinical Trials
| Autor: | Jan Spatz, Andreas Pfützner, Mina Hanna, Johannes Pfützner, Stephanie Strobl, Filiz Demircik, Anke H. Pfützner, Valeria Kirsch |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Biomedical Engineering Bioengineering Hypoglycemia Sensitivity and Specificity law.invention Endocrinology Randomized controlled trial law Internal Medicine Diabetes Mellitus Medicine Humans Wireless internet access Glycemic Randomized Controlled Trials as Topic Clinical Trials as Topic Data collection business.industry Glucose meter Blood Glucose Self-Monitoring Data Collection Reproducibility of Results Repeatability Equipment Design Original Articles Middle Aged medicine.disease Clinical trial Equipment Failure Analysis Emergency medicine Practice Guidelines as Topic Female business Wireless Technology Internet Access |
| Zdroj: | Journal of diabetes science and technology. 13(3) |
| ISSN: | 1932-2968 |
| Popis: | Background: In recent randomized clinical trials, an unusual reporting pattern of glycemic data and hypoglycemic events potentially related to an internet enabled blood glucose meter (MyGlucoHealth, BGM) was observed. Therefore, this clinical study was conducted to evaluate the system accuracy of the BGM in accordance with the ISO15197:2015 guidelines with additional data collection. Methods: To investigate system accuracy, 10 of 3088 devices and 6 of 23 strip lots, used in the trials, were selected by a randomization procedure and a standard repeatability assessment. YSI 2300 STAT Plus was used as the standard reference method. The samples were distributed as per the ISO15197:2015 recommendations with 20 additional samples in the hypoglycemic range. Each sample was tested with 6 devices and 6 strip lots with double determinations. Results: Overall, 121 subjects with blood glucose values 26-423 mg/dL were analyzed, resulting in 1452 data points. In all, 186/1452 readings (12.8%) did not meet the ISO acceptance criteria. Data evaluated according to the FDA guidelines showed that 336/1452 (23.1%) readings did not meet the acceptance criteria. A clear bias toward elevated values was observed for BG Conclusions: The results show that the BGM, although approved according to standard regulatory guidelines, did not meet the level of analytical accuracy required for clinical treatment decisions according to ISO 15197:2015 and FDA requirements. In general, caution should be exercised before selection of BGMs for patients and in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|